A Phase 1 interventional study of LY3002813 and Placebo in Alzheimer Disease, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.
Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 1, and was the 2nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:
Banner Health · Sites in Colombia
Ages 25–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Japan, Puerto Rico
Ages 55+
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Eli Lilly and Company · Sites in China
Ages 55–80
Paul S. Aisen · Sites in United States
Ages 50–80
By country, each count listing its studies:
donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2013; this study’s year is marked. 1 started in 2015.
This study's enrollment of 61 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 240 across the 15 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 56th largest by enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2015, is one of 34 in phase 1, and was the 59th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
1 of the studies testing donanemab in Alzheimer Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026866Phase 3Eli Lilly and CompanyA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing donanemab in Alzheimer Disease, from their registry updates:
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD or mild to moderate AD.
The study involves 3 parts.
Drug will be given as an intravenous infusion (injection into a vein). For Parts A, B and C, the study will last approximately 72 weeks, not including screening of approximately 56 days. The study is for research purposes only and is not intended to treat any medical condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single intravenous (IV) dose of placebo.
Drug: Placebo
Participants received single IV dose of 10 mg/kg LY3002813.
Biological: LY3002813
Participants received single IV dose of 20 mg/kg LY3002813.
Biological: LY3002813
Participants received single IV dose of 40 mg/kg LY3002813.
Biological: LY3002813
Participants received multiple IV dose of placebo every 2 weeks (Q2W) for 24 weeks.
Drug: Placebo
Participants received multiple IV dose of 10 mg/kg LY3002813 Q2W for 24 weeks.
Biological: LY3002813
Participants received multiple IV dose of placebo every 4 weeks (Q4W) for 72 weeks.
Drug: Placebo
Participants received multiple IV dose of 10 mg/kg LY3002813 Q4W for 72 weeks.
Biological: LY3002813
Participants received multiple IV dose of 20 mg/kg LY3002813 Q4W for 72 weeks.
Biological: LY3002813
Administered IV
Administered IV
Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr)
Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. Least square (LS) mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.
Time frame: Baseline, Week 72
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)] in Part A
Area under the curve from time zero to last quantifiable concentration \[AUC (0-tlast)\] at day 1 was reported.
Time frame: Predose, end of infusion, 3, 24 and 48 hours postdose
Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time at a Dosing Interval (AUCtau) at Day 1 of LY3002813 in Part B and Part C
Area under the concentration versus time curve during one dosing interval at day 1 was reported.
Time frame: Predose, end of infusion, 3, 24, 48 and 72 hours postdose
PK:Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3002813 in Part B and C
AUCtau of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.
Time frame: Part B (Day 127): predose, end of infusion, 3, 24, 48 and 72 hours postdose; Part C (Day 141): predose, end of infusion, 3, 24, 48 and 72 hours postdose
PK: Maximum Serum Concentration (Cmax) of LY3002813 at Day 1 of LY3002813
Maximum serum concentration of LY3002813 during one dosing interval at day 1 was reported.
Time frame: Part A: Predose, end of infusion, 3, 24 and 48 hours postdose; Part B and C: Predose, end of infusion, 3, 24, 48 and 72 hours postdose
PK: Maximum Serum Concentration (Cmax) of LY3002813 at Steady State of LY3002813 in Part B and C
Cmax of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.
Time frame: Part B (Day 127): predose, end of infusion, 3, 24, 48 and 72 hours postdose; Part C (Day 141): predose, end of infusion, 3, 24, 48 and 72 hours postdose
Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADAs) to LY3002813
Blood samples were tested to determine if a participant reacted to LY3002813 by producing anti-LY3002813 antibodies. Samples were identified as TE-ADAs if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)\*100.
Time frame: Predose up to Day 589
| Milestone | Part A: Placebo Single Dose (SD) | Part A: 10 Milligram Per Kilogram (mg/kg) LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 4 | 3 | 10 | 5 | 8 | 10 |
| Received at least 1 dose of study drug | 7 | 7 | 7 | 4 | 3 | 10 | 5 | 8 | 10 |
| Completed | 7 | 6 | 6 | 4 | 3 | 9 | 3 | 4 | 4 |
| Not completed | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 4 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. Least square (LS) mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.
| standard uptake value ratio (SUVr) | Part A,B and C: Placebo | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: 10 mg/kg LY3002813 Q2W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr) | -0.050 ± 0.04 | -0.122 ± 0.06 | -0.183 ± 0.06 | -0.255 ± 0.10 | -0.305 ± 0.05 | -0.419 ± 0.06 | -0.379 ± 0.05 |
Area under the curve from time zero to last quantifiable concentration \[AUC (0-tlast)\] at day 1 was reported.
| microgram*hour per milliliter(μg*hr/mL) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD |
|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)] in Part A | 25700 ± 20 | 59400 ± 19 | 110000 ± 32 |
Area under the concentration versus time curve during one dosing interval at day 1 was reported.
| microgram*hour per milliliter (μg*hr/mL) | Part B: 10 mg/kg LY3002813 Q2W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time at a Dosing Interval (AUCtau) at Day 1 of LY3002813 in Part B and Part C | 23000 ± 22 | 32900 ± 35 | 58900 ± 22 |
AUCtau of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.
| μg*hr/mL | Part B: 10 mg/kg LY3002813 Q2W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|
| PK:Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3002813 in Part B and C | 29700 ± 68 | 35800 ± 61 | 68400 ± 37 |
Maximum serum concentration of LY3002813 during one dosing interval at day 1 was reported.
| microgram per milliliter (μg/mL) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: 10 mg/kg LY3002813 Q2W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|---|---|---|
| PK: Maximum Serum Concentration (Cmax) of LY3002813 at Day 1 of LY3002813 | 196 ± 17 | 413 ± 17 | 910 ± 15 | 223 ± 19 | 252 ± 31 | 564 ± 26 |
Cmax of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.
| μg/mL | Part B: 10 mg/kg LY3002813 Q2W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|
| PK: Maximum Serum Concentration (Cmax) of LY3002813 at Steady State of LY3002813 in Part B and C | 273 ± 23 | 366 ± 44 | 598 ± 23 |
Blood samples were tested to determine if a participant reacted to LY3002813 by producing anti-LY3002813 antibodies. Samples were identified as TE-ADAs if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)\*100.
| percentage of participants | Part A,B and C: Placebo | 10 mg/kg LY3002813 IV SD | 20 mg/kg LY3002813 IV SD | 40 mg/kg LY3002813 IV SD | 10 mg/kg LY3002813 IV Q2W | 10 mg/kg LY3002813 IV Q4W | 20 mg/kg LY3002813 IV Q4W |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADAs) to LY3002813 | 13.3 | 85.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Collected over Baseline Upto 584 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo SD | 0/7 (0%) | 2/7 (28.6%) | 5/7 (71.4%) |
| Part A: 10 mg/kg LY3002813 SD | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Part A: 20 mg/kg LY3002813 SD | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Part A: 40 mg/kg LY3002813 SD | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part B: Placebo Q2W | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part B: 10 mg/kg LY3002813 Q2W | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Part C: Placebo Q4W | 1/5 (20%) | 1/5 (20%) | 4/5 (80%) |
| Part C:10 mg/kg LY3002813 Q4W | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Part C:20 mg/kg LY3002813 Q4W | 0/10 (0%) | 2/10 (20%) | 9/10 (90%) |
| Event | Part A: Placebo SD | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/7 | 0/7 | 0/7 | 0/4 | 0/3 | 0/10 | 1/5 | 0/8 | 0/10 |
| Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/4 | 0/3 | 0/2 | 0/2 | 0/4 | 0/3 | 0/4 | 0/6 |
| Hip fractureInjury, poisoning and procedural complications | 1/7 | 0/7 | 0/7 | 0/4 | 0/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| AngerPsychiatric disorders | 0/7 | 0/7 | 0/7 | 0/4 | 0/3 | 0/10 | 0/5 | 1/8 | 0/10 |
| Decreased activityGeneral disorders | 0/7 | 0/7 | 0/7 | 0/4 | 0/3 | 0/10 | 0/5 | 0/8 | 1/10 |
| Urinary tract infectionInfections and infestations | 0/7 | 0/7 | 0/7 | 0/4 | 0/3 | 0/10 | 0/5 | 0/8 | 1/10 |
| Vasogenic cerebral oedemaNervous system disorders | 0/7 | 0/7 | 0/7 | 0/4 | 0/3 | 0/10 | 0/5 | 0/8 | 1/10 |
| Event | Part A: Placebo SD | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W |
|---|---|---|---|---|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/7 | 0/7 | 0/7 | 0/4 | 2/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| Vasogenic cerebral oedemaNervous system disorders | 0/7 | 0/7 | 2/7 | 2/4 | 0/3 | 2/10 | 0/5 | 3/8 | 2/10 |
| Atrophic vulvovaginitisReproductive system and breast disorders | 1/6 | 0/4 | 0/3 | 0/2 | 1/2 | 0/4 | 0/3 | 0/4 | 0/6 |
| GastroenteritisInfections and infestations | 0/7 | 0/7 | 0/7 | 0/4 | 1/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/7 | 0/7 | 0/7 | 0/4 | 1/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| HeadacheNervous system disorders | 0/7 | 1/7 | 2/7 | 0/4 | 1/3 | 1/10 | 0/5 | 0/8 | 1/10 |
| PollakiuriaRenal and urinary disorders | 0/7 | 0/7 | 0/7 | 0/4 | 1/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/7 | 0/7 | 0/7 | 0/4 | 1/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| PruritusSkin and subcutaneous tissue disorders | 0/7 | 0/7 | 0/7 | 0/4 | 1/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| HaematomaVascular disorders | 0/7 | 0/7 | 0/7 | 0/4 | 1/3 | 0/10 | 0/5 | 0/8 | 0/10 |
| Age, Continuous(years) | Part A: Placebo Single Dose (SD) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 79.6 ± 7.7 | 78.3 ± 8.4 | 75.6 ± 6.4 | 75.3 ± 6.7 | 65.7 ± 4.9 | 66.8 ± 8.6 | 72.6 ± 12.2 | 73.0 ± 7.8 | 71.7 ± 9.2 | 73.2 ± 8.9 |
| Sex: Female, Male(Participants) | Part A: Placebo Single Dose (SD) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 4 | 3 | 2 | 2 | 4 | 3 | 4 | 6 | 34 |
| Male | 1 | 3 | 4 | 2 | 1 | 6 | 2 | 4 | 4 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo Single Dose (SD) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Not Hispanic or Latino | 7 | 7 | 7 | 4 | 3 | 9 | 5 | 8 | 9 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Placebo Single Dose (SD) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 1 | 2 | 1 | 3 | 2 | 3 | 2 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 |
| White | 4 | 5 | 6 | 1 | 2 | 7 | 3 | 5 | 7 | 40 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: Placebo Single Dose (SD) | Part A: 10 mg/kg LY3002813 SD | Part A: 20 mg/kg LY3002813 SD | Part A: 40 mg/kg LY3002813 SD | Part B: Placebo Q2W | Part B: 10 mg/kg LY3002813 Q2W | Part C: Placebo Q4W | Part C:10 mg/kg LY3002813 Q4W | Part C:20 mg/kg LY3002813 Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 5 | 5 | 6 | 2 | 2 | 7 | 3 | 5 | 8 | 43 |
| Japan | 2 | 2 | 1 | 2 | 1 | 3 | 2 | 3 | 2 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Aug 2019, 44 months.
Results were first posted in Oct 2024, 5 years 1 month after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 44 months is above that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donanemab